A critical hindrance to the development of a novel vaccine against Mycobacterium tuberculosis is a lack of understanding of protective correlates of immunity and of host factors involved in a successful adaptive immune response. Studies from our group and others have used a mouse-based in vitro model system to assess correlates of protection. Here, using this coculture system and a panel of whole-cell vaccines with varied efficacy, we developed a comprehensive approach to understand correlates of protection. We compared the gene and protein expression profiles of vaccine-generated immune peripheral blood lymphocytes (PBLs) to the profiles found in immune splenocytes. PBLs not only represent a clinically relevant cell population, but comparing the expression in these populations gave insight into compartmentally specific mechanisms of protection. Additionally, we performed a direct comparison of host responses induced when immune cells were cocultured with either the vaccine strain Mycobacterium bovis BCG or virulent M. tuberculosis. These comparisons revealed host-specific and bacterium-specific factors involved in protection against virulent M. tuberculosis. Most significantly, we identified a set of 13 core molecules induced in the most protective vaccines under all of the conditions tested. Further validation of this panel of mediators as a predictor of vaccine efficacy will facilitate vaccine development, and determining how each promotes adaptive immunity will advance our understanding of antimycobacterial immune responses.A lthough it has been more than 90 years since the implementation of immunization with the Mycobacterium bovis BCG vaccine, Mycobacterium tuberculosis is as much of a public health threat today as ever (1). While it is clear that the BCG vaccine has shortcomings, the exact nature of its failure to fully protect adult populations against pulmonary disease still remains a mystery. The lack of understanding of the protective mechanisms needed for the successful control of M. tuberculosis impedes the design and testing of next-generation novel vaccine candidates (2-4).Much work has already been done to elucidate the protective mechanisms involved in the primary and secondary host responses to M. tuberculosis. Several immune components are integral to the primary immune response to M. tuberculosis, as has been demonstrated in both humans and mice. Interferon gamma (IFN-␥) is important for infection control in humans, as individuals with deficiencies in IFN-␥ signaling pathways are more susceptible to disseminated BCG and infections caused by nontuberculous mycobacteria (NTM) (5). In murine studies, IFN-␥ is essential for controlling the growth of the bacteria, as mice deficient in IFN-␥ succumb quickly to infection (6, 7).A primary source of IFN-␥ is activated CD4 ϩ T cells, which are themselves important for controlling M. tuberculosis infections. The role of CD4 ϩ T cells has been clearly demonstrated in humans in the context of HIV and associated T-cell deficiencies, as these patients are h...